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Introduction
Malignant pleural mesothelioma is an aggressive malignancy 
arising from the pleural lining, with a strong causal link 
to prior asbestos use (1). Despite a significant reduction 
in its use in many countries worldwide, the long latency 
period between asbestos exposure and disease has led to 
an increased incidence over the last 20 years, with over 
2,500 deaths in the UK alone in 2015 (2,3). Mesothelioma 
causes significant morbidity to patients, including dyspnoea 
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(often related to malignant pleural effusion), systemic 
symptoms and chest pain (4,5). It is invariably fatal, with a 
median survival of approximately 1 year from diagnosis (6).
Mesothelioma can be difficult to diagnose. Imaging 
techniques are often unable to accurately distinguish the 
disease from other malignant and benign pleural conditions 
and the diagnostic yield from cytological analysis of pleural 
fluid is notoriously poor (7). Therefore, most patients will 
undergo more invasive pleural procedures to facilitate 
diagnosis (8), which could include: image guided pleural 
biopsy, local anaesthetic thoracoscopy (LAT), video-assisted 
thoracoscopic surgery (VATS) or open pleural biopsy. Many 
also require pleural interventions to manage recurrent 
symptomatic pleural effusions.
Procedure tract metastasis (PTM) are a recognised 
complication of pleural interventions in mesothelioma. 
Tumour cells seed along the intervention sites resulting 
in the formation of subcutaneous metastasis, which can 
be painful and unsightly (9). Possible mechanisms of this 
phenomenon include disruption of the tumour sheet 
during the procedure, stimulating tumour growth along 
the plane of the intervention or leakage of pleural fluid 
containing tumour cells along the newly formed tract into 
the subcutaneous tissues (10,11). 
Mesothelioma is known to be radiosensitive in vitro (12), 
but due to the large treatment volumes required to 
encompass all disease and consequent toxicity to other 
thoracic organs, radical radiotherapy as treatment for 
mesothelioma is currently not routinely used. However, it 
has been hypothesised that delivering low dose, targeted 
prophylactic radiotherapy to procedural tracts immediately 
after pleural interventions could destroy local tumour cells 
thereby reducing the subsequent incidence of PTM.
Conflicting results from three historical randomised 
controlled trials (RCT) of prophylactic radiotherapy 
in mesothelioma (13-15) and multiple retrospective 
observational studies (11,16) led to uncertainty about 
its efficacy in reducing PTM’s in mesothelioma. This 
caused variations in recommendations for prophylactic 
r a d i o t h e r a p y  a m o n g s t  h i s t o r i c a l  i n t e r n a t i o n a l 
guidelines (3,17,18) and substantial variation in clinical 
practice (16). In order to resolve this clinical equipoise, 
two large, robust, multicentre RCTs have recently been 
conducted which have expanded the body of evidence 
considerably (6,19). 
This review article critically summarises the literature on 
prophylactic radiotherapy in mesothelioma and highlights 
areas that warrant further evaluation.
 
How common are PTMs in those not receiving 
prophylactic radiotherapy?
The reported incidence of PTM in the literature has ranged 
from 0–48% (16), with much of the evidence derived from 
small retrospective case series (11,16). Two of the largest 
series report similar PTM incidence in those patients not 
receiving prophylactic radiotherapy of around 13% [Ruffie 
et al., 45/332 patients (13.6%) (20); Metintas et al. 28/212 
patients (13.2%)] (20,21). However other retrospective 
studies found higher PTM rates of 40/123 (32.5%) in 
patients not receiving prophylactic radiotherapy (9). This 
variation may be explained by a lack of consistent definitions 
of a PTM, particularly in retrospective series where follow-
up may not be as robust. It is also feasible that scar tissue 
from a procedure could mimic a small subcutaneous tumour 
nodule. 
Five randomised trials have now been reported, which 
on the whole provide more reliable estimations. The first 
published RCT reported a high rate of PTM in the control 
arm of 8/20 (40%) (14). However, the subsequent larger 
RCTs, including 2 trials with over 100 patients in their 
control arm, consistently showed a PTM incidence of 
10–16% in the control arms which is felt to be more 
reflective of that seen in clinical practice (Table 1) 
(6,13,15,19).
Are there any risk factors for PTM development?
Mesothelioma is a heterogenous disease, with different 
histological subtypes with varying prognoses (4,5). 
Diagnostic and treatment pathways often vary between 
individuals and hence identifying those at greatest risk of 
PTM development could be beneficial.
There is data to show that larger-bore procedures 
confer a higher risk of tract metastasis than small 
bore interventions. In a retrospective cohort of 100 
consecutive patients, surgical biopsy (either thoracotomy 
or thoracoscopy) had a PTM rate of 15/69 (22%) whereas 
image guided biopsy had a lower PTM rate of 1/22 (5%) (8). 
A subsequent retrospective study showed a similar pattern, 
with a PTM incidence of 8/31 (26%) in patients undergoing 
thoracotomy compared with 20/181 (11%) in those who had 
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Table 1 Summary of the available data from 5 randomised control trials on prophylactic radiotherapy to tract sites
Trial
Boutin et al.,  
1995 (n=40)
Bydder et al., 2004 
(n=58 procedure 
sites in 43 patients)
O’Rouke et al., 
2007 (n=61)
Clive et al., 2016 (n=203)
Bayman et al., 2017 ^ 
(n=375)
Procedure type (n, %)
Thoracotomy 40 [100] 9 [4]
VATS 22 [38] ^^^ 91 [45] 205 [55] ^^
LAT 16 [26] 74 [36] 101 [27] ^^
Chest drain 15 [25] 3 [1] 27 [7] ^^
IPC 25 [12]
Fine needle aspiration 27 [47]
Open surgical biopsy 15 [4] ^^
Radiologically guided 
pleural biopsy
27 [44] ^^^^ 1 [1]
Abrams needle pleural 
biopsy
9 [16]
Unknown 3 [5] 27 [7] ^^
Tumour type (n, %)
Epithelioid 26 [65] 13 [21] 142 [70] 288 [77] ^^
Sarcomatoid 7 [18] 4 [7] 16 [8]
Mixed 7 [18] 5 [8] 37 [18]
Desmoplastic 4 [2]
Unknown 58 [100] 39 [64] 4 [2] 87 [23] ^^
Prophylactic radiotherapy used
Number of fractions 3 1 3 3 3 
Gray per fraction 7 10 7 7 7
Modality 12.5–15 MeV 
electrons
9 MeV electrons 250 kV photons 
or 9–12 MeV 
electrons
6–18 MeV electrons, kV 
photons or MeV electrons
Electron-voltage not 
specified
Field Square field 16–
100 cm2 to include 
all scar sites
NS 6 cm circle Minimum 7 cm diameter Scar site + superior 
margin of 3 superior ribs 
+3 cm margins inferiorly, 
medially and laterally
Time to prophylactic 
radiotherapy
10–15 days post-
intervention
Within 15 days post-
intervention
Within 21 days 
post-intervention
Within 42 days post-
intervention
Within 42 days post-
intervention
Table 1 (continued)
undergone a thoracoscopy or pleural biopsy (P=0.025) (21). 
The role of other factors in increasing PTM risk is 
less clear. Clive et al. showed that the epithelioid subtype 
of mesothelioma had higher PTM rates, with a PTM 
incidence of 15/72 (21%) in epithelioid versus 1/29 (3%) 
in other histological subtypes in patients not receiving 
prophylactic radiotherapy (6). This was hypothesised to 
be due to the poorer prognosis of the other subtypes, 
resulting in many patients dying before a PTM had time to 
develop. However, these findings have not been consistently 
replicated by other retrospective studies (9,21).
The efficacy of chemotherapy in mesothelioma has 
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Table 1 (continued)
Trial
Boutin et al.,  
1995 (n=40)
Bydder et al., 2004 
(n=58 procedure 
sites in 43 patients)
O’Rouke et al., 
2007 (n=61)
Clive et al., 2016 (n=203)
Bayman et al., 2017 ^ 
(n=375)
Primary endpoint
Time of primary endpoint NS NS 12 months 12 months 6 months
PTM incidence—
treatment arm, n (%)
0/20 [0] 2/28 [7] 4/31 [13] 9/102 [9] 6 months: 10/189 (5.3%); 
12 months: 19/189 
(10.1%)
PTM incidence—control 
arm, n (%)
8/20 [40] 3/30 [10] 3/30 [10] 16/101 [16] 6 months: 6/186 (3.2%); 
12 months: 15/186 (8.1%)
Odds ratio (95% CI) N/A 0.69 (0.11–4.49) ^^ 1.33 (0.27–6.53) 
^^
0.51 (0.19–1.32) 6 months: 0.60 (0.17–
1.86); 12 months: 0.79 
(0.36–1.69)
P value <0.001 0.53 0.748 0.14 6 months: 0.44;  
12 months: 0.59
Number needed to treat 
to prevent a single PTM
2.5 ^^ 35 ^^ N/A All nodules 14.3
Painful nodules 25.1
NS
Number of painful PTM NS NS 2/7 PTMs ‘Slightly 
Painful’ ^^
8/25 PTMs painful NS
Survival (median, 95% CI)
Overall NS 8.7 months (CI NS) 41 weeks [22–56] NS NS
Treatment arm 14 months (CI NS) NS NS Median 12 months (CI NS) NS
Control arm 8 months (CI NS) NS NS Median 12 months (CI NS) NS
Time to PTM (mean/median) (range or IQR)
Overall Mean 6 months 
(range 1–13 
months)
NS Mean 5 months 
(range 1–7 months) 
^^
NS NS
Treatment arm N/A NS Mean 4 months 
(range 1–6 months) 
^^
Median 6 months  
(IQR 4–7 months)
NS
Control arm Mean 6 months 
(range 1–13)
NS Mean 7 months 
control arm  
(range 6–7) ^^
Median 7 months  
(IQR 5–10)
NS
Side effects of prophylactic radiotherapy: skin toxicity (n, %) ^^^^^
Grade 0/no toxicity
NS
NS
NS
38 [41] NS
Grade 1 NS 50 [54] 96 [52]
Grade 2 0 (0) 4 [4] 19 [10]
Grade 3 0 (0) 0 (0) 1 [1]
Grade 4 0 (0) 0 (0) 0 (0)
^, abstract available only; ^^, not reported in original article but calculated based on data available from the articles; ^^^, thoracoscopy 
or thoracic drain; ^^^^, not stated whether blind or radiologically guided biopsy; ^^^^^, refers to early skin toxicity (<3 months: SMART 
trial), or skin toxicity with no time point stated (PIT trial and Bydder et al.). NS, not specified; N/A, not applicable; PTM, pleural tract 
metastasis; VATS, video-assisted thoracoscopic surgery; LAT, local anaesthetic thoracoscopy; IPC, indwelling pleural catheter; IQR, inter-
quartile range; CI, confidence interval.
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improved in the last decade. Previous unproven treatment 
combinations have been replaced by pemetrexed-based 
regimes which have been shown to prolong survival in 
clinical trials (22). Historical retrospective data published 
prior to the routine use of pemetrexed-based chemotherapy 
showed no difference in PTM incidence in those receiving 
chemotherapy and those who did not [19/157 (12.1%) and 
3/29 (10.3%) respectively] (21). However, it is conceivable 
that newer, more effective chemotherapy regimens may 
reduce the risk of PTM due to loco-regional effects of 
chemotherapy preventing tumour implantation. This may 
explain the findings of a subgroup analysis of a recently 
published RCT, which found that in those patients not 
receiving prophylactic radiotherapy, fewer patients who had 
chemotherapy developed PTMs than those not receiving 
chemotherapy [8/64 (13%) and 8/37 (22%) respectively] (6). 
Does prophylactic radiotherapy reduce the 
risk of PTM—evidence from initial randomised 
control trials
The seminal randomised control trial investigating the 
use of prophylactic radiotherapy to prevent PTM was 
published by Boutin et al. (14). In this study 40 patients 
were randomised to either 7 Gray in three fractions over 
three consecutive days, 10–15 days after thoracoscopy, or no 
radiotherapy. They found a significant difference in PTM 
incidence between the treatment arms [0/20 (0%) in the 
prophylactic radiotherapy group versus 8/20 (40%) in the 
control group (P<0.001)]. Despite this seemingly convincing 
evidence, uncertainly remained, given the small sample size 
of the study and the very high incidence of PTM in those 
not receiving prophylactic radiotherapy, which was not 
perceived to reflect that seen in usual clinical practice and 
has not been replicated in subsequent RCTs (6,13,15,19).
Due to these uncertainties following the Boutin 
trial, another two small randomised control trials were 
subsequently conducted (13,15). Bydder et al. randomised 
58 procedure sites from 43 patients to receive either a single 
fraction of 10 Gy radiotherapy using 9 MeV electrons 
or no prophylactic radiotherapy (13). The study found 
no difference between groups, with a PTM incidence of 
2/28 (7%) in the treatment arm versus 3/30 (10%) in the 
control arm (P=0.53). The authors speculated that their 
baseline incidence of PTM may have been lower than that 
reported by Boutin et al. due to their inclusion of small-
bore interventions as opposed to only thoracoscopies (14). 
There may also have been some inherent bias in the study 
as they randomised procedure sites rather than patients, 
when multiple intervention sites in the same individual may 
not behave independently (16). However, despite the lack 
of efficacy of prophylactic radiotherapy in their trial, they 
concluded that the radiotherapy dose used was too small and 
therefore advocated the use of prophylactic radiotherapy for 
high risk procedures at the dose used by Boutin et al. (14). 
Another study, using the same radiation dose as the 
Boutin et al. paper, was conducted to provide more 
clarification on the utility of prophylactic radiotherapy. 
O’Rourke et al. randomised 61 patients to receive 21 Gy 
in three fractions using either 250 kV photons or 9–12 
MeV electrons (15). Over a 12-month follow-up period, 
the PTM incidence was 4/31 (13%) in the treatment arm 
and 3/30 (10%) in the control arm, with no significance 
between the two groups (P=0.748). However, the sample 
size calculation, which utilised the high PTM rate found in 
the control arm of Boutin et al.’s prior study (14) meant the 
study was criticized for being underpowered.
Therefore despite three randomised control trials, 
there was still significant uncertainty about the efficacy of 
prophylactic radiotherapy in mesothelioma. Due to the 
conflicting trial findings, there was still widespread variation 
in the use of prophylactic radiotherapy. A survey of UK 
practice conducted in 2009 showed that 75% of responding 
centres used prophylactic radiotherapy but the timings and 
dose fractionation delivered varied widely (16). 
Additionally, in recent years the management options for 
patients with mesothelioma have improved. Non-evidence-
based chemotherapy has been replaced by pemetrexed-
based regimens which have been shown to prolong survival 
and time to progression in mesothelioma and are now 
frequently offered to suitable patients (22). Also, the use of 
indwelling pleural catheters (IPCs) in the management of 
malignant pleural effusion has dramatically increased in the 
last decade. Hence the role of prophylactic radiotherapy in 
modern mesothelioma management was unclear and there 
was a desire for a suitably powered RCT to conclusively 
address the issue (16). 
The surgical and large bore procedures in 
malignant pleural mesothelioma and radiotherapy 
trial (SMART trial) 
The SMART trial is a recently published RCT that 
evaluated the use of prophylactic radiotherapy to reduce 
PTMs in malignant pleural mesothelioma (6). Its primary 
endpoint was the incidence of PTM within 12 months, 
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but it also evaluated pain, analgesia requirements, health-
related quality of life and included health economic 
analysis. This large multi-centre trial included 22 
centres and randomised 203 patients to ‘immediate’ 
radiotherapy with 21 Gy over 3 working days within 
42 days of pleural intervention, or active surveillance with 
deferred radiotherapy if a PTM developed during follow-
up. This study focussed on large bore pleural procedures, 
including: open pleural biopsy, surgical thoracotomy, VATS, 
LAT, large bore chest drains and IPCs. The definition 
of a PTM was clearly defined and required independent 
clinical examination by 2 people and the trial follow-up was 
rigorous for 12 months after randomisation.
The SMART trial found a PTM incidence rate of 
9/102 (9%) in the treatment arm compared to 16/101 
(16%) in the control arm, which was not statistically 
significant using their pre-defined intention to treat 
analysis [odds ratio (OR) 0.51; 95% confidence interval 
(CI), 0.19–1.32; P=0.14; number needed to treat (NNT) 
to prevent one PTM =14.3]. Interestingly 17/25 PTMs 
were asymptomatic (NNT to prevent one painful PTM 
=25.1) and PTMs tended to develop in the latter stages 
of the disease, with 14/25 (56%) PTMs developing after 
6 months in this cohort who had a median survival of 12 
months. Therefore, even if the trial had recruited more 
patients to increase the study’s power (23,24), the patient 
derived benefit of delivering prophylactic radiotherapy is 
likely to be small. 
The pre-specified per-protocol analysis, whereby patients 
with major protocol violations were excluded, did show a 
statistically significant difference in PTM incidence, with 
a rate of 5/84 (6%) in the intervention arm versus 16/99 
(16%) in the control arm [OR 0.33; (95% CI, 0.09–1.00), 
P=0.037]. This highlights that if prophylactic irradiation is 
to be used, it is vital that it is given within protocol, both 
in terms of timing and field size. Although whether this is 
realistic or feasible in routine clinical practice is not clear, 
particularly given the protocol violations in the context of 
this large, robustly conducted RCT.
Therefore, in view of a lack of statistical significance 
in the intention to treat cohort, and the tendency for 
PTMs to be asymptomatic and develop late, the authors 
concluded the routine use of prophylactic radiotherapy to 
prevent PTM in all patients with mesothelioma was not 
justified. Potential signals were identified in certain patient 
subgroups, which will be discussed in more detail below.
The Prophylactic Irradiation of Tracts in patients 
with pleural mesothelioma (PIT) trial
The PIT trial recruited concurrently with the SMART 
trial and also adds important data regarding the role of 
prophylactic radiotherapy in mesothelioma. Three hundred 
seventy-five patients from 54 UK centres were randomised 
to either receive 21 Gy in three fractions of electrons over 
three consecutive days or no prophylactic radiotherapy 
(19,25). They used a wide field with at least a 3 cm lateral, 
medial and inferior margin, and a superior margin extended 
to include 3 superior ribs (19,25). Included procedures 
were: VATS, open surgical biopsy, LAT or chest drains of 
any calibre. Needle biopsies, large thoracotomies and IPC’s 
were excluded (25). The primary endpoint was chest wall 
metastasis at 6 months. Full results are eagerly awaited 
but a summary abstract of their findings has recently been 
presented (19). 
The abstract reported no significant difference in PTM 
incidence between the treatment arms at 6 months [6/186 
(3.2%) in the treatment arm and 10/189 (5.3%) in the 
control arm (OR 0.60; 95% CI, 0.17–1.86; P=0.44)]. There 
was also no significant difference in their intention to treat 
analysis at 12 months, with a PTM incidence of 15/186 
(8.1%) in the treatment arm versus 19/189 (10.1%) in the 
control arm (OR 0.79; 95% CI, 0.36–1.69; P=0.59) (19). 
The full results from the PIT trial are awaited with 
great interest; particularly those looking at the important 
patient-centred secondary outcome of chest pain. However, 
the provisional primary endpoint data is consistent with 
the results of the SMART trial, adding weight to both 
trials conclusions. Thus 2 large, robustly conducted RCTs 
have shown no compelling evidence that prophylactic 
radiotherapy to tract sites is effective in preventing PTMs 
in all-comers with mesothelioma.
The impact of prophylactic radiotherapy on 
symptoms and quality of life
With its poor life expectancy, a significant consideration for 
any treatment in mesothelioma is the impact on patients 
remaining quality of life. Prophylactic radiotherapy to 
procedure sites is a palliative procedure, to reduce the 
potentially troublesome symptoms PTMs cause. Any such 
treatment should ideally be efficacious, minimally invasive, 
have limited side effects and most importantly impact 
positively on the patient’s symptoms and quality of life.
Prophylactic radiotherapy is well tolerated, with minimal 
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side effects. In the SMART trial, the commonest adverse 
effects related to radiotherapy were grade 1 skin toxicity and 
lethargy (6). However, 3 consecutive hospital attendances 
to receive radiotherapy can be burdensome for patients, 
particularly so soon after a terminal diagnosis, with 28% of 
patients in SMART at least a little inconvenienced by this 
radiotherapy regimen (6).
Traditionally PTM’s were thought to be painful and 
affect quality of life, however trial data suggests for the 
majority of patients this may not be the case. O’Rourke 
et al. were the first RCT to comment on any patient-related 
outcome measures, investigating metastasis symptomology 
and depression and anxiety scores between cohorts (15). 
Only 2 of the 7 metastasis associated with tract sites were 
noted to be ‘slightly painful’, with the other five deemed 
‘not painful’ (15). However, with regard to depression and 
anxiety scores the low rate of questionnaire completion led 
the authors to conclude little weight can be given to their 
findings (15). 
As discussed previously, the SMART trial found 
only 8/25 (32%) of PTMs were painful and the NNT 
to prevent a symptomatic nodule was 25.1 (6). In those 
who developed a PTM in the SMART trial, there was no 
difference in chest pain visual analogue scale (VAS) scores 
or analgesia use between the treatment groups. Additionally, 
there was no significant differences in symptom scores, 
analgesia use or any validated quality of life score in those 
receiving prophylactic radiotherapy compared to delayed 
radiotherapy if a PTM developed. This provides support for 
ongoing active surveillance of patients with mesothelioma 
after diagnosis to ensure symptoms are promptly addressed.
Cost-effectiveness of radiotherapy
The SMART trial is the only trial to date to investigate 
the cost effectiveness and economic impact of prophylactic 
radiotherapy. They report that prophylactic radiotherapy 
was not cost-effective, with no discernible clinically or 
statistically significant differences identified for either 
mean costs, survival or the quality of life between the two 
groups (6,26). Those patients who did develop a PTM had 
neither a reduction in their quality of life or an increase in 
healthcare system costs. With a willingness to pay threshold 
of £30,000 per quality adjusted life year (QALY), there 
was only a 24% chance that prophylactic radiotherapy, as 
opposed to deferred radiotherapy, was cost-effective (26). 
With many feeling that £30,000 is an overestimation, and a 
cost per QALY of £13,000 would be more appropriate (27), 
in this context prophylactic radiotherapy would be even less 
cost-effective.
Are there any specific sub-groups that may 
benefit from prophylactic radiotherapy?
Whilst no trials have been powered to specifically 
investigate specific subpopulations, pre-defined secondary 
per-protocol analysis was undertaken in SMART, which 
identified potential effects of prophylactic radiotherapy in 
certain subgroups (28). 
The SMART tria l  identi f ied that  prophylact ic 
radiotherapy may reduce the incidence of PTMs in the 
subgroup of patients with epithelioid-only histology, 
with 6/71 (8%) developing a PTM in the prophylactic 
radiotherapy arm compared to 15/72 (21%) in deferred 
radiotherapy arm in patients with epithelioid histology 
(OR 0.35; 95% CI, 0.11–1.04, P=0.057) (6). Again, this 
may explained by the improved survival of this subgroup 
compared to other histological subtypes (4,5), meaning 
these patients live long enough to develop PTMs. 
Therefore, it is possible that prophylactic RT may confer 
more benefits in this subgroup.
When evaluating patients  who did not receive 
chemotherapy in the SMART tr ia l ,  prophylact ic 
radiotherapy appeared to significantly reduce the incidence 
of PTM compared to those in the deferred arm, with an 
incidence of 2/46 (4%) versus 8/37 (22%) respectively, 
(P=0.021) (6). The reasons for this may be that systemic 
chemotherapy aids local disease control, negating the need 
for prophylactic radiotherapy, whereas if chemotherapy 
is not given, prophylactic radiotherapy may help destroy 
tumour cells in the subcutaneous tissues, thereby reducing 
the incidence of PTM.
The other subgroup analyses in the SMART trial, 
looking at procedure type and those patients with a follow 
up of >6 months, failed to show any effect of prophylactic 
radiotherapy in preventing PTM. However, whether 
prophylactic radiotherapy is beneficial in the context of the 
largest bore surgical interventions remains unanswered. 
Such small numbers of patients in the SMART trial were 
randomised having had a thoracotomy, that it is not possible 
to make a definitive conclusion regarding this.
Given the small sample size of all these subgroups, 
these data should be interpreted with extreme caution, 
as they certainly need to be replicated before delivering 
prophylactic radiotherapy to these populations should be 
advised. Further data from the PIT trial will be vital to 
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explore these subgroups further. A planned patient-level 
meta-analysis using data from both SMART and PIT will 
help to inform the conclusions further, particularly in these 
smaller subgroups which are currently underpowered to 
reliably inform practice.
Conclusions
After years of debate, two recently conducted, large, 
robust randomised trials have finally added clarity to the 
role of prophylactic radiotherapy in mesothelioma. Both 
provide independent, consistent evidence that providing 
this treatment routinely to all patients following large bore 
pleural interventions is ineffective in preventing PTM in 
the context of modern mesothelioma management. Whilst 
the full results of the PIT trial are eagerly awaited and 
collaboration between PIT and SMART trial teams will 
help clarify potential subgroups that may derive benefit, 
such as patients not receiving chemotherapy or those 
with epithelioid histology, at present the routine use of 
prophylactic radiotherapy cannot be recommended.
The SMART trial has demonstrated that prophylactic 
radiotherapy is not cost effective and confers no patient-
derived benefit in terms of symptomology, analgesia use 
or health-related quality of life parameters. By providing 
pragmatic, patient centred care, with vigilant clinical follow-
up of patients with mesothelioma, patients within the 
deferred arm of the SMART trial were not disadvantaged in 
terms of symptom control. 
It is refreshing after years of ambiguity and debate that 
two, high profile, international mesothelioma guidelines 
recently published in the UK and the USA now consistently 
advise, based on high quality evidence, that prophylactic 
irradiation of tracts should not be offered to patients to 
prevent procedure tract metastases (29,30). By conclusively 
resolving this issue, research attention can now be diverted 
to other areas of the investigation and management of this 
devastating disease.
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